Ronald Rawitt
Psychiatry · New York, NYNPI 1760582555
Payments from drug & device makers
Across 236 payments — averaging $31.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Validus Pharmaceuticals LLC$2K
- Takeda Pharmaceuticals U.S.A., Inc.$953
- Ironshore Pharmaceuticals Inc.$518
- Axsome Therapeutics, Inc.$365
- Sunovion Pharmaceuticals Inc.$364
- plus $1K from 10 others
What the payments were for
- Food & beverage$7,408100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 113 | $2,405 |
| Validus Pharmaceuticals LLC | 18 | $1,535 |
| Takeda Pharmaceuticals U.S.A., Inc. | 40 | $953 |
| Ironshore Pharmaceuticals Inc. | 5 | $518 |
| Axsome Therapeutics, Inc. | 11 | $365 |
| Sunovion Pharmaceuticals Inc. | 3 | $364 |
| Bausch Health US, LLC | 19 | $355 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $175 |
| Corium, LLC | 6 | $170 |
| Shire North American Group Inc | 6 | $131 |
| Otsuka America Pharmaceutical, Inc. | 1 | $125 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $120 |
| Alkermes, Inc. | 1 | $115 |
| Idorsia Pharmaceuticals US Inc | 2 | $44 |
| Supernus Pharmaceuticals, Inc. | 1 | $20 |
| Aprecia Pharmaceuticals, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Equetro$1,229
- LYBALVI$461
- Jornay PM 20mg capsules (Bottle of 100)$435
- LATUDA$364
- VRAYLAR$361
- ZolpiMist$150
- ABILIFY MAINTENA$125
How this compares
$7,408 in reported general payments places this provider in the 90th percentile of 3,713 psychiatry providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Olanzapine-Fluoxetine HclOlanzapine/Fluoxetine Hcl | 11 | $5,931 |
| Divalproex Sodium ErDivalproex Sodium | 38 | $4,995 |
| Quetiapine Fumarate | 12 | $1,513 |
| Risperidone | 14 | $639 |
| Lithium Carbonate ErLithium Carbonate | 15 | $549 |
| Propranolol Hcl | 14 | $357 |
| Buspirone Hcl | 11 | $243 |
| Spironolactone | 12 | $147 |
| Aripiprazole | 11 | $41 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in New York
- Michael LiebowitzNew York$7.1M
- Paul EderNew York$2.7M
- Lenard AdlerNew York$1.8M
- Ram ShrivastavaNew York$1.8M
- Jonathan KaneNew York$1.8M
- Eric HollanderNew York$1.4M
- William HapworthNew York$1.3M
- Manish ZinzuvadiaNew York$1.3M
- Jianping ChenNew York$1.2M
- Anthony ZoghbiNew York$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.